Clinical trial
A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
NCT05223036 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 19, 2023
- Completion date
- April 17, 2026
- Enrollment
- 15 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
attenuated familial adenomatous polyposis, colorectal carcinoma, duodenal carcinoma, familial adenomatous polyposis